Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Visa to Move European Headquarters to London’s Canary Wharf 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
SAN DIEGO, Dec. 02, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the Oppenheimer 26th Annual Healthcare Conference at 2:10 pm EST on Wednesday, December 9, 2015, at the Westin Grand Central Hotel in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The company’s clinical-stage pipeline includes two product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Investor Contact: Casey Logan Andrew McDonald Chief Business Officer LifeSci Advisors LLC (858) 550‐0780 ext. 236 646-597-6987 [email protected] [email protected]
